ClinicalTrials.gg
RecruitingNCT07228221POAGUpdated Nov 14, 2025

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

A Phase 4 interventional study of iStent infinite trabecular micro-bypass system model iS3 and iDose TR (Travoprost intracameral Implant) 75mcg in Open Angle Glaucoma, Pigmentary Glaucoma and Pseudoexfoliation Glaucoma, sponsored by Jonathon Myers. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-14.

Sponsored by Jonathon Myers · Phase 4, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Planned enrollment
43rd of 45
20 · median 135
Started
2026
the only one that year
Phase 4
22 of 46
2 open now
Registered
46th of 46
by date
Lead sponsor
1 of 46
Jonathon Myers

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 43rd largest by planned enrollment of the 45 interventional ones that give a count, is the only one that started in 2026, is one of 22 in phase 4, and was the 46th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.

Read the detailed description

The Investigators will assess the mean intraocular pressure change from baseline, the change in the number of medications from baseline, the proportion of patients needing additional incisional surgery, and the incidence of adverse events. The Investigators hypothesize that patients receiving the combined standalone iStent infinite and iDose will experience a safe and significant reduction in mean intraocular pressure and number of medications during the study time period.

03

Conditions studied

  • Open Angle Glaucoma
  • Pigmentary Glaucoma
  • Pseudoexfoliation Glaucoma

Keywords

  • POAG
  • PG
  • PXG
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate to severe open angle glaucoma (including POAG, PG, and PXG)
  • Open angle configuration (Shaffer grade ≥ 3), normal angle anatomy9
  • Visual acuity HM or better
  • VF MD -6dB or worse
  • Failed medical therapy and/or laser treatment
  • Incisional glaucoma surgery contemplated as next intervention
  • Phakic or pseudophakic

Exclusion criteria

Exclusion Criteria:

  • Traumatic, uveitic, neovascular glaucoma, or angle closure glaucoma
  • Previous incisional glaucoma surgery
  • ; History of iridotomy, SLT, or micropulse laser trabeculoplasty within the prior 90 days
  • Active ocular inflammation or edema, corneal dystrophy
  • Corneal or other pathology preventing accurate Goldmann applanation tonometry
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Surgery for patients with medically uncontrolled POAG

    surgery using combined minimally invasive surgical iStent infinite trabecular micro-bypass systme model iS3 and drug depot iDose TR (Travoprost Intracameral Implant) 75mcg

    Device: iStent infinite trabecular micro-bypass system model iS3 · Drug: iDose TR (Travoprost intracameral Implant) 75mcg

Interventions

  • DeviceiStent infinite trabecular micro-bypass system model iS3

    surgery perfomed using the iStent infinite trabecular micro-bypass system model iS3

  • DrugTravoprostStudies of TravoprostTravoprost pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    surgery performed using the iDose TR (Travoprost intracameral Implant) 75mcg

06

What researchers measure

Primary outcomes

  1. IOP reduction from baseline

    a logistic regression model will be used for the imputation of missing values, using the 12-month performance outcome as dependent variable, and sex, race, age, baseline IOP, number of IOP-lowering medications used at baseline, last IOP and number of medications at the 6-month visit or later as explanatory variables.

    Time frame: Diurnal IOP reduction from baseline at 12 months

07

Study locations

1 of 1 sites recruiting
  • Wills Eye Hosital Glaucoma Dept.
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The study protocol, Statistical Analysis Plan (SAP), informed Consent Form, and deidentified participant and group data will be kept on file at Wills Eye Hospital for 7 years. Researchers can request this data by email to glaucoma@willseye.org with a description of their planned use.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: This is a 5 year study with anticipated completion of enrollment and data December 2031.

Access criteria: Researchers can request the study protocol, Statistical Analysis Plan (SAP), informed Consent Form, and deidentified participant and group data with a description of their planned use

Data sharing details ↗ · willseye.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Aug 2031, 67 months later.

Of 45 phase 4 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's planned 67 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 14, 2025
StartEst.
Jan 5, 2026
Primary completionEst.
Aug 30, 2031
CompletionEst.
Dec 31, 2031
Last update
Nov 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07228221
Lead sponsor
Jonathon Myers
Collaborators
Glaukos Corporation
Responsible party
Jonathon Myers (Co-Investigator, Wills Eye) — Sponsor-investigator
First posted
Nov 14, 2025
Start date
Jan 5, 2026 (estimated)
Primary completion
Aug 30, 2031 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Nov 14, 2025

Study contacts

Meskerem Divers
Contact
mdivers@willseye.org
215-825-4712
Jeanne L Molineaux, COA
Contact
jmolineaux@willseye.org
215-825-4713
Dilru Amarasekera, MD
principal investigator · Wills Eye Hospital Glaucoma Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion